Project: PROSPECTOR 2 - PROlonged versus Single dose in PEnicillin oral Challenge Testing parallel randomized feasibility placebo cOntrolled tRial
Trubiano Group
Penicillin allergies are a major burden on patients and health care worldwide. Currently, up to 1 in 4 hospitalised patients admitted to hospital will report an antibiotic allergy, many of which limit appropriate antibiotic use and lead to poorer health outcomes. In some instances, patients will be given a single or multiple test doses to determine if a patient is truly allergic. This study will further research to determine if a single dose or multiple dose challenge (5-days) is able to elicit true penicillin allergy and examine the unintended consequences associated with each type of challenge.
Project Site: Austin Health
Contact project supervisor for further
information and application enquiries
Trubiano Group
2 vacancies
We are a wet and dry lab based at Austin Health within the Department of Infectious Diseases (Austin Health) with an interest in drug allergy/hypersensitivity research from translational, clinical trials to health services programs. In particular our "dry lab" focuses on low-risk penicillin and antibiotic allergy clinical trials and our "wet lab" on the development of translational ex vivo and in vitro T-cell diagnostics to assertain drug causality in Severe Cutaneous Adverse Reactions. Our lab collaborates with groups internationally, including North America, Europe and South Africa.
Research degrees at the Doherty Institute are administered by the University of Melbourne.